APO Research
Talk to an analyst

APO RESEARCH · REPORT

Multiple Sclerosis Therapeutics

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Multiple Sclerosis Therapeutics Market Analysis and Forecast 2026-2032

2 January 2026197 pages

Choose your research edition.

Industry ResearchMultiple Sclerosis Therapeutics Industry Research Report 2026117 pages · $2,950 USDIndustry Growth & TrendsGlobal Multiple Sclerosis Therapeutics Industry Growth and Trends Forecast to 203288 pages · $3,450 USDMarket StructureGlobal Multiple Sclerosis Therapeutics Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032187 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Multiple Sclerosis Therapeutics Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Multiple Sclerosis Therapeutics Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Multiple Sclerosis Therapeutics market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Multiple Sclerosis Therapeutics is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Multiple Sclerosis Therapeutics is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Multiple Sclerosis Therapeutics is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Multiple Sclerosis Therapeutics is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Multiple Sclerosis Therapeutics include Biogen Idec, Sanofi Genzyme, Teva Pharmaceuticals, AbbVie, Bayer, Pfizer, Merck and Novartis, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Multiple Sclerosis Therapeutics, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Multiple Sclerosis Therapeutics, also provides the revenue of main regions and countries. Of the upcoming market potential for Multiple Sclerosis Therapeutics, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Multiple Sclerosis Therapeutics revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Multiple Sclerosis Therapeutics market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Multiple Sclerosis Therapeutics revenue, projected growth trends, production technology, application and end-user industry.

Multiple Sclerosis Therapeutics Segment by Company

Biogen Idec

Sanofi Genzyme

Teva Pharmaceuticals

AbbVie

Bayer

Pfizer

Merck

Novartis

Multiple Sclerosis Therapeutics Segment by Type

Beta Interferon

Monoclonal Antibodies

Antineoplastic Agents

Corticosteroids

Others

Multiple Sclerosis Therapeutics Segment by Application

Hospital Pharmacies

Retail Pharmacies

e-Commerce

Multiple Sclerosis Therapeutics Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Multiple Sclerosis Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Multiple Sclerosis Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Multiple Sclerosis Therapeutics.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Multiple Sclerosis Therapeutics in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Multiple Sclerosis Therapeutics company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Multiple Sclerosis Therapeutics revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Multiple Sclerosis Therapeutics Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Beta Interferon Major Player Table 3. Monoclonal Antibodies Major Player Table 4. Antineoplastic Agents Major Player Table 5. Corticosteroids Major Player Table 6. Others Major Player Table 7. Global Multiple Sclerosis Therapeutics Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 8. Hospital Pharmacies Major Player Table 9. Retail Pharmacies Major Player Table 10. e-Commerce Major Player Table 11. Multiple Sclerosis Therapeutics Industry Trends Table 12. Multiple Sclerosis Therapeutics Industry Drivers Table 13. Multiple Sclerosis Therapeutics Industry Opportunities and Challenges Table 14. Multiple Sclerosis Therapeutics Industry Restraints Table 15. Global Multiple Sclerosis Therapeutics Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 16. Global Multiple Sclerosis Therapeutics Market Size by Region (2021-2026) & (US$ Million) Table 17. Global Multiple Sclerosis Therapeutics Market Share by Region (2021-2026) Table 18. Global Multiple Sclerosis Therapeutics Market Size by Region (2027-2032) & (US$ Million) Table 19. Global Multiple Sclerosis Therapeutics Market Share by Region (2027-2032) Table 20. Global Multiple Sclerosis Therapeutics Revenue by Players (US$ Million) & (2021-2026) Table 21. Global Multiple Sclerosis Therapeutics Revenue Market Share by Players (2021-2026) Table 22. Global Multiple Sclerosis Therapeutics Key Players Ranking, 2024 VS 2025 VS 2026 Table 23. Global Multiple Sclerosis Therapeutics Key Players Headquarters & Area Served Table 24. Global Multiple Sclerosis Therapeutics Players, Product Type & Application Table 25. Global Multiple Sclerosis Therapeutics Players Establishment Date Table 26. Global Players Market Concentration Ratio (CR5 and HHI) Table 27. Global Multiple Sclerosis Therapeutics by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 28. Global Multiple Sclerosis Therapeutics Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global Multiple Sclerosis Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 30. Global Multiple Sclerosis Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 31. Global Multiple Sclerosis Therapeutics Revenue Market Share by Type (2021-2026) Table 32. Global Multiple Sclerosis Therapeutics Revenue Market Share by Type (2027-2032) Table 33. Global Multiple Sclerosis Therapeutics Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global Multiple Sclerosis Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 35. Global Multiple Sclerosis Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 36. Global Multiple Sclerosis Therapeutics Revenue Market Share by Application (2021-2026) Table 37. Global Multiple Sclerosis Therapeutics Revenue Market Share by Application (2027-2032) Table 38. Biogen Idec Company Information Table 39. Biogen Idec Business Overview Table 40. Biogen Idec Multiple Sclerosis Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 41. Biogen Idec Multiple Sclerosis Therapeutics Product Portfolio Table 42. Biogen Idec Recent Development Table 43. Sanofi Genzyme Company Information Table 44. Sanofi Genzyme Business Overview Table 45. Sanofi Genzyme Multiple Sclerosis Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 46. Sanofi Genzyme Multiple Sclerosis Therapeutics Product Portfolio Table 47. Sanofi Genzyme Recent Development Table 48. Teva Pharmaceuticals Company Information Table 49. Teva Pharmaceuticals Business Overview Table 50. Teva Pharmaceuticals Multiple Sclerosis Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 51. Teva Pharmaceuticals Multiple Sclerosis Therapeutics Product Portfolio Table 52. Teva Pharmaceuticals Recent Development Table 53. AbbVie Company Information Table 54. AbbVie Business Overview Table 55. AbbVie Multiple Sclerosis Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 56. AbbVie Multiple Sclerosis Therapeutics Product Portfolio Table 57. AbbVie Recent Development Table 58. Bayer Company Information Table 59. Bayer Business Overview Table 60. Bayer Multiple Sclerosis Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 61. Bayer Multiple Sclerosis Therapeutics Product Portfolio Table 62. Bayer Recent Development Table 63. Pfizer Company Information Table 64. Pfizer Business Overview Table 65. Pfizer Multiple Sclerosis Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 66. Pfizer Multiple Sclerosis Therapeutics Product Portfolio Table 67. Pfizer Recent Development Table 68. Merck Company Information Table 69. Merck Business Overview Table 70. Merck Multiple Sclerosis Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 71. Merck Multiple Sclerosis Therapeutics Product Portfolio Table 72. Merck Recent Development Table 73. Novartis Company Information Table 74. Novartis Business Overview Table 75. Novartis Multiple Sclerosis Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 76. Novartis Multiple Sclerosis Therapeutics Product Portfolio Table 77. Novartis Recent Development Table 78. North America Multiple Sclerosis Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 79. North America Multiple Sclerosis Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 80. North America Multiple Sclerosis Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 81. North America Multiple Sclerosis Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 82. North America Multiple Sclerosis Therapeutics Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 83. North America Multiple Sclerosis Therapeutics Revenue by Country (2021-2026) & (US$ Million) Table 84. North America Multiple Sclerosis Therapeutics Revenue by Country (US$ Million) & (2027-2032) Table 85. Europe Multiple Sclerosis Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 86. Europe Multiple Sclerosis Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 87. Europe Multiple Sclerosis Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 88. Europe Multiple Sclerosis Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 89. Europe Multiple Sclerosis Therapeutics Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 90. Europe Multiple Sclerosis Therapeutics Revenue by Country (2021-2026) & (US$ Million) Table 91. Europe Multiple Sclerosis Therapeutics Revenue by Country (US$ Million) & (2027-2032) Table 92. China Multiple Sclerosis Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 93. China Multiple Sclerosis Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 94. China Multiple Sclerosis Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 95. China Multiple Sclerosis Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 96. Asia Multiple Sclerosis Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 97. Asia Multiple Sclerosis Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 98. Asia Multiple Sclerosis Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 99. Asia Multiple Sclerosis Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 100. Asia Multiple Sclerosis Therapeutics Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 101. Asia Multiple Sclerosis Therapeutics Revenue by Region (US$ Million) & (2021-2026) Table 102. Asia Multiple Sclerosis Therapeutics Revenue by Region (US$ Million) & (2027-2032) Table 103. SAMEA Multiple Sclerosis Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 104. SAMEA Multiple Sclerosis Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 105. SAMEA Multiple Sclerosis Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 106. SAMEA Multiple Sclerosis Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 107. SAMEA Multiple Sclerosis Therapeutics Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 108. SAMEA Multiple Sclerosis Therapeutics Revenue by Country (2021-2026) & (US$ Million) Table 109. SAMEA Multiple Sclerosis Therapeutics Revenue by Country (US$ Million) & (2027-2032) Table 110. Research Programs/Design for This Report Table 111. Authors List of This Report Table 112. Secondary Sources Table 113. Primary Sources List of Figures Figure 1. Multiple Sclerosis Therapeutics Image Figure 2. Global Multiple Sclerosis Therapeutics Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Multiple Sclerosis Therapeutics Market Size Share 2021 VS 2025 VS 2032 Figure 4. Beta Interferon Image Figure 5. Monoclonal Antibodies Image Figure 6. Antineoplastic Agents Image Figure 7. Corticosteroids Image Figure 8. Others Image Figure 9. Global Multiple Sclerosis Therapeutics Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 10. Global Multiple Sclerosis Therapeutics Market Size Share 2021 VS 2025 VS 2032 Figure 11. Hospital Pharmacies Image Figure 12. Retail Pharmacies Image Figure 13. e-Commerce Image Figure 14. Global Multiple Sclerosis Therapeutics Market Size (US$ Million) & (2021-2032) Figure 15. Global Multiple Sclerosis Therapeutics Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 16. Global Multiple Sclerosis Therapeutics Market Share by Region: 2021 VS 2025 VS 2032 Figure 17. Global Multiple Sclerosis Therapeutics Players Revenue Share Top 10 and Top 5 in 2025 Figure 18. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 19. Global Multiple Sclerosis Therapeutics Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Multiple Sclerosis Therapeutics Revenue Market Share 2021 VS 2025 VS 2032 Figure 21. Global Multiple Sclerosis Therapeutics Revenue Market Share by Type (2021-2032) Figure 22. Global Multiple Sclerosis Therapeutics Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global Multiple Sclerosis Therapeutics Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 24. Global Multiple Sclerosis Therapeutics Revenue Market Share by Application (2021-2032) Figure 25. North America Multiple Sclerosis Therapeutics Revenue YoY Growth (2021-2032) & (US$ Million) Figure 26. North America Multiple Sclerosis Therapeutics Revenue Share by Type (2021-2032) Figure 27. North America Multiple Sclerosis Therapeutics Revenue Share by Application (2021-2032) Figure 28. North America Multiple Sclerosis Therapeutics Revenue Share by Country (2021-2032) Figure 29. United States Multiple Sclerosis Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Canada Multiple Sclerosis Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 31. Mexico Multiple Sclerosis Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 32. Europe Multiple Sclerosis Therapeutics Revenue YoY Growth (2021-2032) & (US$ Million) Figure 33. Europe Multiple Sclerosis Therapeutics Revenue Share by Type (2021-2032) Figure 34. Europe Multiple Sclerosis Therapeutics Revenue Share by Application (2021-2032) Figure 35. Europe Multiple Sclerosis Therapeutics Revenue Share by Country (2021-2032) Figure 36. Germany Multiple Sclerosis Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. France Multiple Sclerosis Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. U.K. Multiple Sclerosis Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Italy Multiple Sclerosis Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Spain Multiple Sclerosis Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Russia Multiple Sclerosis Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Netherlands Multiple Sclerosis Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. Nordic Countries Multiple Sclerosis Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 44. China Multiple Sclerosis Therapeutics Revenue YoY Growth (2021-2032) & (US$ Million) Figure 45. China Multiple Sclerosis Therapeutics Revenue Share by Type (2021-2032) Figure 46. China Multiple Sclerosis Therapeutics Revenue Share by Application (2021-2032) Figure 47. Asia Multiple Sclerosis Therapeutics Revenue YoY Growth (2021-2032) & (US$ Million) Figure 48. Asia Multiple Sclerosis Therapeutics Revenue Share by Type (2021-2032) Figure 49. Asia Multiple Sclerosis Therapeutics Revenue Share by Application (2021-2032) Figure 50. Asia Multiple Sclerosis Therapeutics Revenue Share by Region (2021-2032) Figure 51. Japan Multiple Sclerosis Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. South Korea Multiple Sclerosis Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. India Multiple Sclerosis Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Australia Multiple Sclerosis Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. Taiwan Multiple Sclerosis Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. Southeast Asia Multiple Sclerosis Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 57. SAMEA Multiple Sclerosis Therapeutics Revenue YoY Growth (2021-2032) & (US$ Million) Figure 58. SAMEA Multiple Sclerosis Therapeutics Revenue Share by Type (2021-2032) Figure 59. SAMEA Multiple Sclerosis Therapeutics Revenue Share by Application (2021-2032) Figure 60. SAMEA Multiple Sclerosis Therapeutics Revenue Share by Country (2021-2032) Figure 61. Brazil Multiple Sclerosis Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Argentina Multiple Sclerosis Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Chile Multiple Sclerosis Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Colombia Multiple Sclerosis Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Peru Multiple Sclerosis Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Saudi Arabia Multiple Sclerosis Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Israel Multiple Sclerosis Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. UAE Multiple Sclerosis Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Turkey Multiple Sclerosis Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Iran Multiple Sclerosis Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Egypt Multiple Sclerosis Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • Beta Interferon
  • Monoclonal Antibodies
  • Antineoplastic Agents
  • Corticosteroids
  • Others
Applications
  • Hospital Pharmacies
  • Retail Pharmacies
  • e-Commerce
Companies covered
  • Biogen Idec
  • Sanofi Genzyme
  • Teva Pharmaceuticals
  • AbbVie
  • Bayer
  • Pfizer
  • Merck
  • Novartis

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Multiple Sclerosis Therapeutics Market by Type
  3. 1.2.1 Global Multiple Sclerosis Therapeutics Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Beta Interferon
  5. 1.2.3 Monoclonal Antibodies
  6. 1.2.4 Antineoplastic Agents
  7. 1.2.5 Corticosteroids
  8. 1.2.6 Others
  9. 1.3 Multiple Sclerosis Therapeutics Market by Application
  10. 1.3.1 Global Multiple Sclerosis Therapeutics Market Size by Application, 2021 VS 2025 VS 2032
  11. 1.3.2 Hospital Pharmacies
  12. 1.3.3 Retail Pharmacies
  13. 1.3.4 e-Commerce
  14. 1.4 Assumptions and Limitations
  15. 1.5 Study Goals and Objectives
2 Multiple Sclerosis Therapeutics Market Dynamics
  1. 2.1 Multiple Sclerosis Therapeutics Industry Trends
  2. 2.2 Multiple Sclerosis Therapeutics Industry Drivers
  3. 2.3 Multiple Sclerosis Therapeutics Industry Opportunities and Challenges
  4. 2.4 Multiple Sclerosis Therapeutics Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Multiple Sclerosis Therapeutics Market Perspective (2021-2032)
  2. 3.2 Global Multiple Sclerosis Therapeutics Growth Trends by Region
  3. 3.2.1 Global Multiple Sclerosis Therapeutics Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Multiple Sclerosis Therapeutics Market Size by Region (2021-2026)
  5. 3.2.3 Global Multiple Sclerosis Therapeutics Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Multiple Sclerosis Therapeutics Revenue by Players
  2. 4.1.1 Global Multiple Sclerosis Therapeutics Revenue by Players (2021-2026)
  3. 4.1.2 Global Multiple Sclerosis Therapeutics Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Multiple Sclerosis Therapeutics Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Multiple Sclerosis Therapeutics Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Multiple Sclerosis Therapeutics Key Players Headquarters & Area Served
  7. 4.4 Global Multiple Sclerosis Therapeutics Players, Product Type & Application
  8. 4.5 Global Multiple Sclerosis Therapeutics Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Multiple Sclerosis Therapeutics Market CR5 and HHI
  11. 4.6.3 2025 Multiple Sclerosis Therapeutics Tier 1, Tier 2, and Tier 3
5 Multiple Sclerosis Therapeutics Market Size by Type
  1. 5.1 Global Multiple Sclerosis Therapeutics Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Multiple Sclerosis Therapeutics Revenue by Type (2021-2032)
  3. 5.3 Global Multiple Sclerosis Therapeutics Revenue Market Share by Type (2021-2032)
6 Multiple Sclerosis Therapeutics Market Size by Application
  1. 6.1 Global Multiple Sclerosis Therapeutics Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Multiple Sclerosis Therapeutics Revenue by Application (2021-2032)
  3. 6.3 Global Multiple Sclerosis Therapeutics Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Biogen Idec
  2. 7.1.1 Biogen Idec Company Information
  3. 7.1.2 Biogen Idec Business Overview
  4. 7.1.3 Biogen Idec Multiple Sclerosis Therapeutics Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Biogen Idec Multiple Sclerosis Therapeutics Product Portfolio
  6. 7.1.5 Biogen Idec Recent Developments
  7. 7.2 Sanofi Genzyme
  8. 7.2.1 Sanofi Genzyme Company Information
  9. 7.2.2 Sanofi Genzyme Business Overview
  10. 7.2.3 Sanofi Genzyme Multiple Sclerosis Therapeutics Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Sanofi Genzyme Multiple Sclerosis Therapeutics Product Portfolio
  12. 7.2.5 Sanofi Genzyme Recent Developments
  13. 7.3 Teva Pharmaceuticals
  14. 7.3.1 Teva Pharmaceuticals Company Information
  15. 7.3.2 Teva Pharmaceuticals Business Overview
  16. 7.3.3 Teva Pharmaceuticals Multiple Sclerosis Therapeutics Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Teva Pharmaceuticals Multiple Sclerosis Therapeutics Product Portfolio
  18. 7.3.5 Teva Pharmaceuticals Recent Developments
  19. 7.4 AbbVie
  20. 7.4.1 AbbVie Company Information
  21. 7.4.2 AbbVie Business Overview
  22. 7.4.3 AbbVie Multiple Sclerosis Therapeutics Revenue and Gross Margin (2021-2026)
  23. 7.4.4 AbbVie Multiple Sclerosis Therapeutics Product Portfolio
  24. 7.4.5 AbbVie Recent Developments
  25. 7.5 Bayer
  26. 7.5.1 Bayer Company Information
  27. 7.5.2 Bayer Business Overview
  28. 7.5.3 Bayer Multiple Sclerosis Therapeutics Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Bayer Multiple Sclerosis Therapeutics Product Portfolio
  30. 7.5.5 Bayer Recent Developments
  31. 7.6 Pfizer
  32. 7.6.1 Pfizer Company Information
  33. 7.6.2 Pfizer Business Overview
  34. 7.6.3 Pfizer Multiple Sclerosis Therapeutics Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Pfizer Multiple Sclerosis Therapeutics Product Portfolio
  36. 7.6.5 Pfizer Recent Developments
  37. 7.7 Merck
  38. 7.7.1 Merck Company Information
  39. 7.7.2 Merck Business Overview
  40. 7.7.3 Merck Multiple Sclerosis Therapeutics Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Merck Multiple Sclerosis Therapeutics Product Portfolio
  42. 7.7.5 Merck Recent Developments
  43. 7.8 Novartis
  44. 7.8.1 Novartis Company Information
  45. 7.8.2 Novartis Business Overview
  46. 7.8.3 Novartis Multiple Sclerosis Therapeutics Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Novartis Multiple Sclerosis Therapeutics Product Portfolio
  48. 7.8.5 Novartis Recent Developments
8 North America
  1. 8.1 North America Multiple Sclerosis Therapeutics Revenue (2021-2032)
  2. 8.2 North America Multiple Sclerosis Therapeutics Revenue by Type (2021-2032)
  3. 8.2.1 North America Multiple Sclerosis Therapeutics Revenue by Type (2021-2026)
  4. 8.2.2 North America Multiple Sclerosis Therapeutics Revenue by Type (2027-2032)
  5. 8.3 North America Multiple Sclerosis Therapeutics Revenue Share by Type (2021-2032)
  6. 8.4 North America Multiple Sclerosis Therapeutics Revenue by Application (2021-2032)
  7. 8.4.1 North America Multiple Sclerosis Therapeutics Revenue by Application (2021-2026)
  8. 8.4.2 North America Multiple Sclerosis Therapeutics Revenue by Application (2027-2032)
  9. 8.5 North America Multiple Sclerosis Therapeutics Revenue Share by Application (2021-2032)
  10. 8.6 North America Multiple Sclerosis Therapeutics Revenue by Country
  11. 8.6.1 North America Multiple Sclerosis Therapeutics Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Multiple Sclerosis Therapeutics Revenue by Country (2021-2026)
  13. 8.6.3 North America Multiple Sclerosis Therapeutics Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
9 Europe
  1. 9.1 Europe Multiple Sclerosis Therapeutics Revenue (2021-2032)
  2. 9.2 Europe Multiple Sclerosis Therapeutics Revenue by Type (2021-2032)
  3. 9.2.1 Europe Multiple Sclerosis Therapeutics Revenue by Type (2021-2026)
  4. 9.2.2 Europe Multiple Sclerosis Therapeutics Revenue by Type (2027-2032)
  5. 9.3 Europe Multiple Sclerosis Therapeutics Revenue Share by Type (2021-2032)
  6. 9.4 Europe Multiple Sclerosis Therapeutics Revenue by Application (2021-2032)
  7. 9.4.1 Europe Multiple Sclerosis Therapeutics Revenue by Application (2021-2026)
  8. 9.4.2 Europe Multiple Sclerosis Therapeutics Revenue by Application (2027-2032)
  9. 9.5 Europe Multiple Sclerosis Therapeutics Revenue Share by Application (2021-2032)
  10. 9.6 Europe Multiple Sclerosis Therapeutics Revenue by Country
  11. 9.6.1 Europe Multiple Sclerosis Therapeutics Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Multiple Sclerosis Therapeutics Revenue by Country (2021-2026)
  13. 9.6.3 Europe Multiple Sclerosis Therapeutics Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Netherlands
  19. 9.6.9 Nordic Countries
10 China
  1. 10.1 China Multiple Sclerosis Therapeutics Revenue (2021-2032)
  2. 10.2 China Multiple Sclerosis Therapeutics Revenue by Type (2021-2032)
  3. 10.2.1 China Multiple Sclerosis Therapeutics Revenue by Type (2021-2026)
  4. 10.2.2 China Multiple Sclerosis Therapeutics Revenue by Type (2027-2032)
  5. 10.3 China Multiple Sclerosis Therapeutics Revenue Share by Type (2021-2032)
  6. 10.4 China Multiple Sclerosis Therapeutics Revenue by Application (2021-2032)
  7. 10.4.1 China Multiple Sclerosis Therapeutics Revenue by Application (2021-2026)
  8. 10.4.2 China Multiple Sclerosis Therapeutics Revenue by Application (2027-2032)
  9. 10.5 China Multiple Sclerosis Therapeutics Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Multiple Sclerosis Therapeutics Revenue (2021-2032)
  2. 11.2 Asia Multiple Sclerosis Therapeutics Revenue by Type (2021-2032)
  3. 11.2.1 Asia Multiple Sclerosis Therapeutics Revenue by Type (2021-2026)
  4. 11.2.2 Asia Multiple Sclerosis Therapeutics Revenue by Type (2027-2032)
  5. 11.3 Asia Multiple Sclerosis Therapeutics Revenue Share by Type (2021-2032)
  6. 11.4 Asia Multiple Sclerosis Therapeutics Revenue by Application (2021-2032)
  7. 11.4.1 Asia Multiple Sclerosis Therapeutics Revenue by Application (2021-2026)
  8. 11.4.2 Asia Multiple Sclerosis Therapeutics Revenue by Application (2027-2032)
  9. 11.5 Asia Multiple Sclerosis Therapeutics Revenue Share by Application (2021-2032)
  10. 11.6 Asia Multiple Sclerosis Therapeutics Revenue by Country
  11. 11.6.1 Asia Multiple Sclerosis Therapeutics Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Multiple Sclerosis Therapeutics Revenue by Country (2021-2026)
  13. 11.6.3 Asia Multiple Sclerosis Therapeutics Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Multiple Sclerosis Therapeutics Revenue (2021-2032)
  2. 12.2 SAMEA Multiple Sclerosis Therapeutics Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Multiple Sclerosis Therapeutics Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Multiple Sclerosis Therapeutics Revenue by Type (2027-2032)
  5. 12.3 SAMEA Multiple Sclerosis Therapeutics Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Multiple Sclerosis Therapeutics Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Multiple Sclerosis Therapeutics Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Multiple Sclerosis Therapeutics Revenue by Application (2027-2032)
  9. 12.5 SAMEA Multiple Sclerosis Therapeutics Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Multiple Sclerosis Therapeutics Revenue by Country
  11. 12.6.1 SAMEA Multiple Sclerosis Therapeutics Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Multiple Sclerosis Therapeutics Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Multiple Sclerosis Therapeutics Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst